Glaukos Corporation announced record net sales of $143.1 million in Q4 2025, a 36% increase year-over-year, and $507.4 million for the full year 2025, up 32%. The company also reaffirmed its 2026 net sales guidance of $600 million to $620 million.

Glaukos reported record net sales of $133.5 million in Q3 2025, marking a 38% increase year-over-year. This growth was primarily driven by strong performance in the glaucoma segment, particularly in the U.S. market. The company also raised its full-year 2025 net sales guidance and provided preliminary 2026 guidance, reflecting continued positive momentum.

Glaukos Corporation achieved record net sales of $124.1 million in Q2 2025, a 30% increase year-over-year. The company significantly reduced its net loss to $19.7 million from $50.5 million in the prior year, and improved its GAAP and non-GAAP gross margins. This performance was primarily fueled by a 36% increase in Glaucoma net sales, with U.S. Glaucoma sales surging by 45%.

Glaukos reported a strong start to 2025 with record net sales of $106.7 million in the first quarter, representing a 25% increase year-over-year. The company's operating loss improved significantly to $20.7 million from $39.1 million in the same period last year. Glaucoma sales were a key driver of growth, increasing 31% year-over-year.

Glaukos achieved record Q4 2024 net sales of $105.5 million, representing a 28% year-over-year increase. The company reported a net loss of $33.6 million, a reduction from the prior year's loss, while non-GAAP net loss improved to $22.2 million. Operating loss also narrowed, and the company ended the quarter with a strong cash position of $324 million.

Glaukos Corporation reported record net sales of $96.7 million for the third quarter of 2024, a 24% increase year-over-year. The company's glaucoma sales reached $76.0 million, up 30% year-over-year, while corneal health sales increased by 5% to $20.6 million. The company raised its 2024 net sales guidance to $377 million to $379 million.

Glaukos Corporation reported record net sales of $95.7 million in Q2 2024, a 19% increase year-over-year. The company raised its 2024 net sales guidance to $370 million to $376 million.

Glaukos reported record net sales of $85.6 million in Q1 2024, a 16% increase year-over-year. The company raised its 2024 net sales guidance to $357 to $365 million. Gross margin was approximately 76%, and non-GAAP gross margin was approximately 83%.

Glaukos Corporation reported record net sales of $82.4 million for Q4 2023, a 16% increase year-over-year. The company reaffirmed its 2024 net sales guidance of $350 million to $360 million.

Glaukos Corporation reported a 10% increase in net sales to $78.0 million for Q3 2023, with glaucoma net sales up 9% and corneal health net sales up 12%. The company raised its 2023 net sales guidance to $307 million to $310 million.

Glaukos reported Q2 2023 net sales of $80.4 million, an 11% increase year-over-year, with a gross margin of approximately 75% and a non-GAAP gross margin of approximately 82%. The company raised its 2023 net sales guidance to $304 million to $308 million.

Glaukos Corporation reported a 9% year-over-year increase in net sales for Q1 2023, reaching $73.9 million. The company's glaucoma and corneal health segments both saw growth, and the company raised its 2023 net sales guidance to $295 million to $300 million.

Glaukos Corporation reported net sales of $71.2 million in Q4 2022, a 3% decrease compared to the same period in 2021. The company's gross margin was approximately 76%, and non-GAAP gross margin was approximately 84%. The company introduced 2023 net sales guidance range of $290 million to $295 million.

Glaukos Corporation reported net sales of $71.3 million in Q3 2022, a 4.6% decrease compared to the same period in 2021. The company's gross margin was approximately 76%, and non-GAAP gross margin was approximately 84%.

Glaukos Corporation announced its second quarter 2022 financial results, with net sales of $72.7 million. The company's gross margin was approximately 75%, and non-GAAP gross margin was approximately 83%. Glaukos raised its 2022 net sales guidance to $275 million to $280 million.

Glaukos Corporation announced financial results for the first quarter ended March 31, 2022, with net sales of $67.7 million. The company updated its 2022 net sales guidance to $270 million to $275 million.

Glaukos Corporation reported fourth-quarter net sales of $73.2 million, consistent with the prior year. The company's gross margin improved, but operating losses increased due to higher SG&A and R&D expenses. The company expects 2022 net sales to be in the range of $265 million to $275 million.

Glaukos Corporation reported a 15% increase in net sales, reaching $74.7 million in Q3 2021. Glaucoma net sales were $58.5 million, and Corneal Health net sales were $16.2 million. The company's gross margin was approximately 79%, and its non-GAAP gross margin was approximately 87%. Net income was $6.2 million, or $0.13 per diluted share.

Glaukos Corporation reported a significant increase in net sales for Q2 2021, with a 147% increase to $78.1 million compared to $31.6 million in Q2 2020. The company's gross margin also improved to approximately 77%, and non-GAAP gross margin reached approximately 84%.

Glaukos Corporation reported a strong start to the year with a 23% increase in net sales, reaching $68.0 million. The growth was fueled by solid performance in both the Glaucoma and Corneal Health segments. The company's gross margin stood at approximately 76%, with a non-GAAP gross margin of approximately 84%.

Glaukos Corporation reported Q4 2020 financial results with net sales increasing by 11% to $73.2 million compared to Q4 2019. The company's gross margin was approximately 73%, and non-GAAP gross margin was approximately 83%. The net loss for the quarter was $10.6 million, or ($0.24) per diluted share, compared to a net income of $36.6 million, or $0.84 per diluted share, in Q4 2019.

Glaukos Corporation reported an 11% increase in net sales for the third quarter of 2020, reaching $64.8 million compared to $58.5 million in the same period of 2019. The company's gross margin was approximately 72%, with a non-GAAP gross margin of approximately 85%. Operating expenses were $59.3 million, and the net loss was $15.7 million, or ($0.35) per diluted share.

Glaukos Corporation reported a decrease in net sales for Q2 2020, primarily due to disruptions associated with COVID-19. The company is encouraged by the initial return of elective procedures and remains focused on advancing its mission.

Glaukos Corporation reported a 2% increase in net sales for Q1 2020, reaching $55.3 million compared to $54.0 million in Q1 2019. However, the company experienced a significant decrease in gross margin, dropping to 41% from 87% in the same period last year. The net loss was $54.1 million, or ($1.24) per diluted share, compared to a net loss of $1.3 million, or ($0.04) per diluted share, in Q1 2019. The company withdrew its annual net sales guidance for 2020 due to uncertainties related to the COVID-19 pandemic.

Glaukos Corporation announced its Q4 and full year 2019 financial results, highlighted by a 22% increase in net sales for the quarter, reaching $65.8 million. The growth was fueled by increased Glaucoma unit volume and the contribution from the Avedro acquisition. The company introduced 2020 net sales guidance of $290 million to $300 million.